Genomic and genetic biomarkers of toxicity

Toxicology

Volumn 245, Issue 3, 2008, Pages 175-181

  Mendrick, Donna L ^a  

^a Department of Toxicogenomics ^*  (United States)

Author keywords

Biomarker; Microarray; Pharmacogenetics; Pharmacogenomics; Toxicogenomics; Translational

Indexed keywords

ADIPSIN; AZATHIOPRINE; BIOLOGICAL MARKER; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; FETUIN; GLUCURONOSYLTRANSFERASE; IRINOTECAN; METHYLTRANSFERASE; WARFARIN;

ARTICLE; BLOOD CELL; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG INFORMATION; DRUG RESPONSE; DRUG SAFETY; GENE EXPRESSION; GENETIC MARKER; GENETIC VARIABILITY; GENOTOXICITY; HEREDITY; HUMAN; LIVER TOXICITY; MICROARRAY ANALYSIS; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; TISSUE INJURY;

ANIMALS; BIOLOGICAL MARKERS; DRUG EVALUATION, PRECLINICAL; GENETIC MARKERS; GENOMICS; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT;

ANIMALIA;

EID: 39649111940     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2007.11.013     Document Type: Article

References (49)

1. Baird A.E. Blood genomics in human stroke. Stroke 38 (2007) 694-698
2. Burczynski M.E., and Dorner A.J. Transcriptional profiling of peripheral blood cells in clinical pharmacogenomic studies. Pharmacogenomics 7 (2006) 187-202
3. Bushel P.R., Heinloth A.N., Li J., Huang L., Chou J.W., Boorman G.A., Malarkey D.E., Houle C.D., Ward S.M., Wilson R.E., Fannin R.D., Russo M.W., Watkins P.B., Tennant R.W., and Paules R.S. Blood gene expression signatures predict exposure levels. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 18211-18216
4. Caldwell M.D., Berg R.L., Zhang K.Q., Glurich I., Schmelzer J.R., Yale S.H., Vidaillet H.J., and Burmester J.K. Evaluation of genetic factors for warfarin dose prediction. Clin. Med. Res. 5 (2007) 8-16
5. Carmo H., Brulport M., Hermes M., Oesch F., de Boer D., Remiao F., Carvalho F., Schon M.R., Krebsfaenger N., Doehmer J., Bastos M.L., and Hengstler J.G. CYP2D6 increases toxicity of the designer drug 4-methylthioamphetamine (4-MTA). Toxicology 229 (2007) 236-244
6. Chen J.J., Wang S.J., Tsai C.A., and Lin C.J. Selection of differentially expressed genes in microarray data analysis. Pharmacogenom. J. 7 (2006) 212-220
7. Coe K.J., Nelson S.D., Ulrich R.G., He Y.D., Dai X., Cheng O., Caguyong M., Roberts C.J., and Slatter J.G. Profiling the hepatic effects of flutamide in rats: a microarray comparison with classical AhR ligands and atypical CYP1A inducers. Drug Metab. Dispos. (2006)
8. Critical Path Institute, 2007. http://www.c-path.org/.
9. de Leon J. AmpliChip CYP450 test: personalized medicine has arrived in psychiatry. Expert. Rev. Mol. Diagn. 6 (2006) 277-286
10. de Leon J., Susce M.T., and Murray-Carmichael E. The AmpliChip CYP450 genotyping test: integrating a new clinical tool. Mol. Diagn. Ther. 10 (2006) 135-151
11. Deeken J.F., Figg W.D., Bates S.E., and Sparreboom A. Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics. Anticancer Drugs 18 (2007) 111-126
12. Denecke B., Graber S., Schafer C., Heiss A., Woltje M., and Jahnen-Dechent W. Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A. Biochem. J. 376 (2003) 135-145
13. Deng M.C., Eisen H.J., Mehra M.R., Billingham M., Marboe C.C., Berry G., Kobashigawa J., Johnson F.L., Starling R.C., Murali S., Pauly D.F., Baron H., Wohlgemuth J.G., Woodward R.N., Klingler T.M., Walther D., Lal P.G., Rosenberg S., and Hunt S. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am. J. Transplant. 6 (2006) 150-160
14. DiMasi J.A. The value of improving the productivity of the drug development process: faster times and better decisions. Pharmacoeconomics 20 Suppl. 3 (2002) 1-10
15. Eichelbaum M., Ingelman-Sundberg M., and Evans W.E. Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 57 (2006) 11.1-11.19
16. Evans R.W., Williams G.E., Baron H.M., Deng M.C., Eisen H.J., Hunt S.A., Khan M.M., Kobashigawa J.A., Marton E.N., Mehra M.R., and Mital S.R. The economic implications of noninvasive molecular testing for cardiac allograft rejection. Am. J. Transplant. 5 (2005) 1553-1558
17. FDA, 2004. Innovation or stagnation? Challenge and opportunity on the critical path to new medical products. http://www.fda.gov/cder/genomics.
18. FDA, 2007. Table of validated biomarkers in drug labels. http://www.fda.gov/cder/genomics/genomic_biomarkers_table.htm.
19. Fielden M.R., Brennan R., and Gollub J. A gene expression biomarker provides early prediction and mechanistic assessment of hepatic tumor induction by nongenotoxic chemicals. Toxicol. Sci. 99 (2007) 90-100
20. Gasche Y., Daali Y., Fathi M., Chiappe A., Cottini S., Dayer P., and Desmeules J. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N. Engl. J. Med. 351 (2004) 2827-2831
21. Goodsaid F., and Frueh F. Process map proposal for the validation of genomic biomarkers. Pharmacogenomics 7 (2006) 773-782
22. Hewitt S.M., Takikita M., Braunschweig T., and Chung J.Y. Promises and challenges of predictive tissue biomarkers. Biomarkers Med. 1 (2007) 313-318
23. Hultin-Rosenberg L., Jagannathan S., Nilsson K.C., Matis S.A., Sjogren N., Huby R.D., Salter A.H., and Tugwood J.D. Predictive models of hepatotoxicity using gene expression data from primary rat hepatocytes. Xenobiotica 36 (2006) 1122-1139
24. Kirchheiner J., and Seeringer A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim. Biophys. Acta (BBA) - Gen. Subjects 1770 (2007) 489-494
25. Leone A.M., Kao L.M., McMillian M.K., Nie A.Y., Parker J.B., Kelley M.F., Usuki E., Parkinson A., Lord P.G., and Johnson M.D. Evaluation of felbamate and other antiepileptic drug toxicity potential based on hepatic protein covalent binding and gene expression. Chem. Res. Toxicol. 20 (2007) 600-608
26. Martin R., Rose D., Yu K., and Barros S. Toxicogenomics strategies for predicting drug toxicity. Pharmacogenomics 7 (2006) 1003-1016
27. McHale C.M., Zhang L., Hubbard A.E., Zhao X., Baccarelli A., Pesatori A.C., Smith M.T., and Landi M.T. Microarray analysis of gene expression in peripheral blood mononuclear cells from dioxin-exposed human subjects. Toxicology 229 (2007) 101-113
28. Mendrick D.L., and Daniels K.K. From the bench to the clinic and back again: translational biomarker discovery using in silico mining of pharmacogenomic data. Biomarkers Med. 1 (2007) 319-333
29. Moore T.J., Cohen M.R., and Furberg C.D. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch. Intern. Med. 167 (2007) 1752-1759
30. Olivier E., Soury E., Ruminy P., Husson A., Parmentier F., Daveau M., and Salier J.P. Fetuin-B, a second member of the fetuin family in mammals. Biochem. J. 350 Pt 2 (2000) 589-597
31. Paules R.S. Toxicogenomics and environmental diseases: the search for biomarkers predictive of adverse effects. Med. Lav. 97 (2006) 322-323
32. Pennie W., Pettit S.D., and Lord P.G. Toxicogenomics in risk assessment: an overview of an HESI collaborative research program. Environ. Health Perspect. 112 (2004) 417-419
33. Personalized Medicine Coalition, 2007. 21st Century medicine: personalized and evidence-based. http://www.personalizedmedicinecoalition.org/programs/ebm_seminar_2007.
34. Phillips K.A. The intersection of biotechnology and pharmacogenomics: health policy implications. Health Aff. (Millwood.) 25 (2006) 1271-1280
35. Phillips K.A., and Van Bebber S.L. A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. Pharmacogenomics 5 (2004) 1139-1149
36. Phillips K.A., and Van Bebber S.L. Measuring the value of pharmacogenomics. Nat. Rev. Drug Discov. 4 (2005) 500-509
37. Pollack, A., 2007. Drug makers seek clues to side effects in genes. www.nytimes.com/2007/09/27/health/research/27effect.html.
38. Searfoss G.H., Jordan W.H., Calligaro D.O., Galbreath E.J., Schirtzinger L.M., Berridge B.R., Gao H., Higgins M.A., May P.C., and Ryan T.P. Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J. Biol. Chem. 278 (2003) 46107-46116
39. Secretary's Advisory Committee on Genetics, Health and Safety, 2007. Realizing the promise of pharmacogenomics: opportunities and challenges. Draft Report. www4.od.nih.gov/oba/sacghs/reports/CR_report.pdf.
40. Severe Adverse Event Consortium, 2007. www.fda.gov/oc/factsheets/initiative.html.
41. Simon R. Development and evaluation of therapeutically relevant predictive classifiers using gene expression profiling. J. Natl. Cancer Inst. 98 (2006) 1169-1171
42. Sistare F.D., and DeGeorge J.J. Preclinical predictors of clinical safety: opportunities for improvement. Clin. Pharmacol. Ther. 82 (2007) 210-214
43. Steimer W., Zopf K., von Amelunxen S., Pfeiffer H., Bachofer J., Popp J., Messner B., Kissling W., and Leucht S. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin. Chem. 51 (2005) 376-385
44. Suter L., Babiss L.E., and Wheeldon E.B. Toxicogenomics in predictive toxicology in drug development. Chem. Biol. 11 (2004) 161-171
45. Vaidya V.S., and Bonventre J.V. Mechanistic biomarkers for cytotoxic acute kidney injury. Expert. Opin. Drug Metab. Toxicol. 2 (2006) 697-713
46. Wilkinson G.R. Drug metabolism and variability among patients in drug response. N. Engl. J. Med. 352 (2005) 2211-2221
47. Yang Y., Abel S.J., Ciurlionis R., and Waring J.F. Development of a toxicogenomics in vitro assay for the efficient characterization of compounds. Pharmacogenomics 7 (2006) 177-186
48. Yang Y., Blomme E.A., and Waring J.F. Toxicogenomics in drug discovery: from preclinical studies to clinical trials. Chem. Biol. Interact. 150 (2004) 71-85
49. Zidek N., Hellmann J., Kramer P.J., and Hewitt P.G. Acute hepatotoxicity: a predictive model based on focused Illumina microarrays. Toxicol. Sci. 99 (2007) 289-302